T he major limiting factor of percutaneous transluminal coronary angioplasty (PTCA) is the high (30% to 50%) restenosis rate within the first 6 months after a successful procedure.12 Effective inhibition of restenosis has not been achieved despite extensive studies of the pathology after experimental and human angioplasty,3-7 pathogenesis,8-12 time course,13-'5 and clinical predictors16"7 of restenosis.
Recently, angiopeptin, a synthetic cyclic octapeptide analogue of somatostatin-14, has been shown to inhibit cellular proliferation after balloon injury of normal arteries in both in vitro and in vivo animal studies when given subcutaneously.18-21 Angiopeptin also reduces myointimal hyperplasia in vein grafts22 and inhibits accelerated coronary artery transplant atherosclerosis,23-25 both of which are a smooth muscle cell proliferative process resembling restenosis after PTCA. This octapeptide analogue differs from somatostatin-14 in binding affinity to the two known somatostatin receptors and has a prolonged plasma half-life compared with somatostatin-14.26 A safer and possibly more effective method of administering drugs is local delivery at the time and the site of PTCA.27 The Wolinsky porous infusion balloon offers this possibility and has been used successfully to deliver various drugs intramurally at the time of balloon injury. [28] [29] [30] [31] [32] [33] The local delivery of drugs into the arterial wall may eventually enable one-time drug treatment at the time of angioplasty at a higher dose than that tolerated by a prolonged systemic application. The local delivery of angiopeptin may result in a more efficacious inhibition of myointimal hyperplasia, since most of the systemically administered angiopeptin concentrates in the liver, not in vascular walls, as demonstrated in rats,34 and much higher concentrations will be obtained in the vascular wall.
The following experiments were designed to study the feasibility and the efficacy of local delivery via a porous infusion balloon of a single dose of angiopeptin on myointimal hyperplasia after balloon injury in a rabbit model. In all previous published studies, angiopeptin was administered over a period of several days up to the vessel after porous infusion balloon delivery. Second, the effect of a single dose of locally delivered angiopeptin on the degree of inhibition of myointimal hyperplasia in the balloon-injured segment and the balloon-injured site distal to the porous infusion balloon site was determined.
Methods

Animals
Adult male New Zealand White rabbits weighing 2.5 to 2.8 kg (Hazelton Farms, Vienna, Va) were housed at constant temperature and a 12-hour cycle of light and darkness in the Research Resources Facility of Georgetown University Medical Center for a period of 1 week for adaptation before the procedures. The rabbits had access to regular rabbit chow (Purina Mills, Inc, Richmond, Ind) and water ad libitum during the entire period. The studies involving the rabbits conformed to the guidelines of the American Physiological Society and were approved by Georgetown University Animal Care and Use Committee.
Autoradiographic Localization ofAngiopeptin
Radiolabeled angiopeptin was prepared by iodinating the tyrosine ring of the authentic angiopeptin (10 ,ug/5 pAL) (Henri Beaufour Institute-USA, Inc, Washington, DC) (Fig 1) 4 . Graph shows mean plasma concentration of angiopeptin vs time after local administration of the drug to rabbits -o-, 1 pg/mL; -,-, 10 pg/mL; -r-, 100 pg/mL).
Sections were cut at 1-,um thickness with glass knives and stained with toluidine blue for light microscopic examination. Silver-gray sections from selected blocks were picked up on 200 to 300 mesh naked copper grids and stained with uranyl acetate and lead citrate. Tissues were examined with a JEOL 1200 EX Electron Microscope (Jeol, Tokyo).
Morphometric Analysis
Sections stained with hematoxylin and eosin were evaluated with a computerized morphometric analyzer (The Morphometer, Woods Hole Educational Associates, Woods Hole, Mass). The medial area was defined as the area between the internal and the external elastic laminae. Myointimal area was defined as the area between the intima and the internal elastic lamina. Percent myointimal hyperplasia was determined as (myointimal area/medial area) x 100. The morphometric evaluation was performed by two independent blinded observers.
perplasia among the control animals versus the different combinations of the angiopeptin groups were done using the Student's t test. Statistical significance is represented by probability values <.05.
Results
Autoradiography
There were areas of intense radioactive particles throughout the vessel wall interspersed by adjacent areas devoid of any radioactivity. This suggests a linear or jet intramural penetration of`PI-angiopeptin. Radioactivity was found both in the cytoplasm and in the nuclei of the medial smooth muscle cells as well as in the adventitia (Fig 3) . Plasma Angiopeptin Levels
The mean plasma concentrations of angiopeptin versus time after local administration of angiopeptin as determined by radioimmunoassay are shown in Table. The absorption half-life of locally delivered angiopeptin varies according to the dose of drug administered. Although direct comparisons cannot be made, the absorption half-life, the distribution half-life, and the elimination half-life of angiopeptin when administered locally are less than when administered subcutaneously in rats but greater than when administered intravenously in rats. 34 Thus, it is most likely that when angiopeptin is administered locally, its kinetics are between those associated with subcutaneous and intravenous administration.
In one animal receiving the angiopeptin at 100 ug/mL concentration and another receiving the angiopeptin at 10 ,ug/mL, angiopeptin was extracted from the locally treated aortic tissue (638 pg/0.2 g of tissue from the 100 ,ug/mL animal and 439 pg/0.2 g of tissue from the 10 gg/mL animal), suggesting that the locally delivered angiopeptin may stay in the vessel wall for at least 24 
Statistics
The data for the morphometric analysis are presented as mean±SEM. The degree of myointimal hyperplasia among the four groups was analyzed by ANOVA Fig 5. The values of percent myointimal hyperplasia (mean±SEM) were 8.2±1.0 for the control group; 7.5±1.5 for the angiopeptin group receiving 1 jig/mL; 6.5 ± 1.7 for the angiopeptin group receiving 10 1Ag/mL; and 6.2±1.4 for the highest-dose angiopeptin group. The morphometry done by the two independent readers had a correlation coefficient of .9 and P<.001. The readings were averaged for data analysis. In the control group, the myointimal hyperplasia consisted of circumferentially uniform, multiple layers of smooth muscle cells (Fig 6, A) . In some of the angiopeptin-treated groups, there was a substantial decrease in the myointimal hyperplasia and the myointimal thickening was patchy, varying within regions of a given vessel section (Fig 6, B) . In the angiopeptin-treated animals, there was a dose-dependent reduction of percent myointimal hyperplasia. However, by ANOVA, there was no statistical difference among the angiopeptin groups compared with the control group.
There were no differences in the amount of volume delivered via the porous infusion balloon among the groups (with volume of 6.1±1.8 mL/min, mean±SD) and no correlation between the volume delivered (or the total amount of angiopeptin locally delivered in the angiopeptin groups) and the percent myointimal hyperplasia in any of the groups. Downstream area. The percent myointimal hyperplasia is shown in Fig 7. The values of percent myointimal hyperplasia (mean±SEM) were 11.4+0.6 for the control group; 7.9+±2.0 for the lowest-dose angiopeptin group; 7.9+1.9 for the angiopeptin group receiving 10 ,ug/mL; and 5.4+1.2 for the highest angiopeptin concentration group. The correlation of the two independent readings was excellent (r=.9, P<.001), and mean values of the readings were used for data analysis. Again % MYOINTIMAL HYPERPLASIA in the control animals, there was a circumferentially uniform myointimal hyperplasia. In the angiopeptintreated animals, the myointimal hyperplasia was markedly reduced and, contrary to the local delivery area, was also uniform circumferentially (Fig 6, C) . The degrees of myointimal hyperplasia were different among the four groups (P<.05 by ANOVA). When the pairwise t test was performed for the different combinations of comparison groups, the significant difference was found only in the highest angiopeptin dose group compared with the control group (P<.001).
Electron Microscopic Studies
Local delivery area. The control group had markedly abnormal intima and showed loss of endothelial integrity. In many areas, the endothelial cell layer was missing and was replaced by a pseudointima of smooth muscle cells, which were either modified smooth muscle cells with the presence of vesicles and microtubules or typical secretory smooth muscle cells with many mitochondria, dilated endoplasmic reticulum, and large Golgi complexes (Fig 8, left) . These smooth muscle cells also exhibited fingerlike projections into the lumen (Fig  8, left) . Furthermore, there was a significant difference in the structure and frequency of a number of cellular organelles of the smooth muscle cells in the control and the angiopeptin-treated groups. In the control group, the rough endoplasmic reticulum was most prominent (Fig 8, left) . The number of plasmalemma vesicles also appeared to be increased, especially in smooth muscle cells in the control group, where they were occasionally shown to occupy the entire cytoplasm. The subendothelial space was consistently wider in the control group than in the angiopeptin-treated groups. In the control group, the subendothelial space consisted of numerous layers of smooth muscle cells (Fig 8, right) .
In the angiopeptin-treated groups, the intima was covered by a morphologically intact endothelial cell layer, although there were occasional gaps between endothelial cells (Fig 9, left) . In the angiopeptin 10 ,g/mL group, the endothelial cells were normal in that they were flattened and elongated with close proximity with the adjacent cells, indicating tight junctions. The cytoplasm contained moderate amounts of mitochondria, endoplasmic reticulum, ribosomes, and pinocytic vesicles along the cell membrane (Fig 9, right) . The endothelial cells of the angiopeptin 1 ,ug/mL and 100 1g/mL groups appeared to have fewer vacuoles and occasionally breaks between the endothelial cells. Many of the endothelial cells appeared to be similar to regenerating cells, with prominent nuclei and the cells bulging into the lumen (Fig 9, left) . Even in areas with underlying myointimal hyperplasia, the endothelial cells appeared ultrastructurally normal. The subendothelial space in the angiopeptin-treated groups varied from none to a few layers of smooth muscle cells. Downstream area. Similar ultrastructural differences between the control and the angiopeptin-treated animals in the local delivery area were also found in the downstream area. In the control animals, the myointimal hyperplasia was highly cellular and the lumen was lined with cells consisting of dense bodies observed among a few peripherally situated bundles of filaments; thus, these cells can be identified as smooth muscle cells (Fig  10, left) . In the angiopeptin-treated animals, the endothelial cells were flattened and normal-appearing, especially in the highest-concentration angiopeptin group, whether there was no myointimal hyperplasia (Fig 10,  right) or a small amount of myointimal hyperplasia. Discussion This study shows that (1) it is feasible to deliver angiopeptin intramurally via the Wolinsky porous infusion balloon; (2) angiopeptin delivered locally does not reduce myointimal hyperplasia at the local delivery site but reduces myointimal hyperplasia significantly only in the downstream area; and (3) angiopeptin may facilitate reendothelialization.
Our original hypothesis was that the locally delivered angiopeptin would reduce myointimal hyperplasia at the local delivery site because of its antiproliferative effect compared with the control group. Furthermore, the downstream area, where balloon injury alone without local delivery was performed, could act as a control site within each animal so that this site would have a similar amount of myointimal hyperplasia among the four groups.
The unexpected observation that myointimal hyperplasia was significantly reduced only in the downstream area and not in the local delivery area may have plausible explanations. In the treatment groups, the myointimal hyperplasia in the local delivery area was patchy with noncircumferential distribution, whereas in the downstream area, the reduction was concentric with uniform circumferential myointimal hyperplasia. We have observed in our previous angiopeptin studies using subcutaneous administration that the inhibition of the myointimal hyperplasia tended to be concentric. [20] [21] [22] [23] [24] The patchy inhibition in this study may be due to the noncircumferential arrangement of pores on the balloon. Furthermore, since heparin was avoided in our study because of its reported inhibition of myointimal hyperplasia,38 plugging of the pores with thrombus and fibrin clots was seen. When the Wolinsky porous infusion balloon was removed after local delivery, it was noted that extremely high pressure (at times greater insulin-like growth factor-l; EGE, epidermal growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; TGFa, transforming growth factor-a; and IEL, internal elastic lamina. mm versus 2.56 mm, respectively). There may be greater initial vascular injury from the balloon denudation and a larger degree of myointimal hyperplasia (11.4% versus 8.2% in the control group, respectively), thus facilitating a greater difference between control and angiopeptintreated groups. It is difficult to determine what fraction of the locally delivered drug actually stays at the local delivery site and has local effect. It is possible that some of the drug may be transported distally via the vasa vasora or by diffusing into the adventitia. The presence of radioactivity in the adventitia also suggests the possibility of localization of angiopeptin in the vasa vasora and possible transport to the peri-local delivery area. The average volume delivered is high compared with previous studies conducted in the brachial arteries in dogs,28 and because of the many branch vessels in the abdominal aorta where local delivery was performed, some of the agent may have been delivered systemically via these vessels. A more convincing evidence of systemic delivery from the local infusion is that the volume of the aorta receiving local delivery is approximately 0.1 mL (using the conventional formula for volume calculation and assuming that the wall thickness is 500 gum). Thus, even if the wall could retain volume equivalent to its own, only 1.7% of the mean volume infused would have stayed at the local delivery site. Also, during the feasibility study in which the local delivery was performed under direct observation, the vessel wall was stretched paper-thin, making possible the extravasation of some of the volume into the adventitia and surrounding tissue.
There may be several mechanisms by which angiopeptin, a somatostatin analogue, inhibits smooth muscle cell proliferation. First of all, somatostatin itself is known to inhibit secretion of many hormones from different cell types41-45; thus, it is very likely but not yet shown conclusively that angiopeptin inhibits the secretion of growth factors such as platelet-derived growth factor, insulin-like growth factor-1, epidermal growth factor, fibroblast growth factor, and transforming growth factor-a from the different cells such as endothelial cells, monocytes/macrophages, and the smooth muscle cells themselves46 (Fig 11) . The growth factors, insulin-like growth factor-1, platelet-derived growth factor, insulin, epidermal growth factor, and fibroblast growth factor are all ligands for receptors, where the intracellular domain is a tyrosine kinase. Binding of these growth factor ligands to their receptors causes autophosphorylation of the tyrosine kinase domain. This initiates the signal transduction chain of events, which results in cell proliferation. It has been shown that somatostatin and some somatostatin analogues, including angiopeptin, activate a membrane-bound phosphatase, which dephosphorylates the activated tyrosine kinase.47 This latter mechanism would explain why angiopeptin seems so successful in inhibiting smooth muscle cell proliferation in comparison to, for example, monoclonal antibodies directed against a specific growth factor-like fibroblast growth factor or platelet-derived growth factor. Dephosphorylation of the activated tyrosine kinase receptors means that angiopeptin will exert inhibitory activity toward a series of growth factors, namely, at least the tyrosine kinase receptor-dependent ligands. 46 The autoradiography studies show that angiopeptin localizes in the smooth muscle cells and inhibits proliferation of smooth muscle cells. 18 Rapid regrowth of the endothelium after vessel wall injury may prevent the migration of smooth muscle cells to the intima63,64 and may inhibit the growth of smooth muscle cells by secreting a heparin-like molecule,w,66 thus preventing myointimal hyperplasia. The transmission electron microscopy also shows that in angiopeptin-treated animals, the internal elastic laminae may not appear as injured as in the control animals. However, it was shown that even intact internal elastic laminae in rabbit aorta allow the migration of medial smooth muscle cells.67 Thus, the internal elastic laminae may not play as important a role as the endothelial layer in inhibiting myointimal hyperplasia in this animal model.
Study Limitations
There are several limitations to our study. This rabbit model of balloon injury is not analogous to that of human restenosis because there is no preexisting atheromatous plaque and neither heparin nor aspirin was used. Furthermore, the small amount of myointimal hyperplasia (with much variability even in the same treatment group in this model) may limit the ability to distinguish the true effect of angiopeptin. However, restenosis after PTCA is likely to involve the same mechanism of myointimal hyperplasia as that seen in our experimental model. 10 No angiogram was performed to guide the balloon size, although we felt that the 3.25-mm balloon size selected was adequate to cause sufficient barotrauma from our observation during the feasibility study. We intentionally selected a much larger balloon to ensure endothelial and medial damage for maximal myointimal hyperplasia. Also, several anatomic markers were used to ensure correct localization of local delivery, such as the fourth vertebral body in each animal. The methods of defining the area of balloon injury and distinguishing the local area from the downstream area are not precise and remain limitations of the study. To minimize the potential overlap, the harvested 1-cm aortic segments from the local effect and the downstream effect were separated by at least a balloon length (2 cm Although the observations from this preliminary study are promising, further studies are needed to define the role of local delivery of angiopeptin and to elucidate the mechanism of angiopeptin. Other routes of administration of angiopeptin need to be examined, as neither subcutaneous nor local administration alone completely abolishes myointimal hyperplasia. Combination of these two routes or continuous infusion with a subcutaneous pump may further reduce the amount of myointimal hyperplasia. Most likely, a pretreatment may be required. It is also unknown how much of the volume (thus, the drug) delivered remains in the vessel wall. Also unknown is how long the drug should remain in the vessel wall to have an effect. It is possible that the duration may not be as important as the timing of the local delivery in relation to the vessel injury. Conclusions In summary, in this preliminary study, we have shown that at the time of balloon injury, it is feasible to infuse angiopeptin intramurally via the Wolinsky porous infusion balloon and that locally administered angiopeptin reduces myointimal hyperplasia not at the local delivery site but distal to the local delivery site, possibly by a downstream transport via the vasa vasora, by facilitating the healing of the injured endothelial cells and/or by a systemic effect. Additional studies are required to ascertain the role and the optimal method of local delivery, especially in atherosclerotic arteries.
